NFKB1 and hepatocellular carcinoma: Specifically, after treatment of NM combined with gemcitabine in gallbladder cancer (25), with paclitaxel in gastric cancer (16) or with TNF-α in hepatocellular carcinoma (17), depression of NF-κB activation was stimulated.